Aging delay: of mice and men
Keywords:
Geroprotectors, testing, rodents, humansAbstract
The evaluation of the safety of a drug in rodents that may be used as geroprotectors is a challenge of current times. In the paper, we discuss approaches to long-term assays for selection of potent aging delay drugs for humans. Priority is given to methods combining evaluation of carcinogenic safety and life-spanning potential. The use of such methods will be time-efficient and economically feasible.
References
2. Vaiserman AM, Lushchak OV, Koliada AV. Anti-aging pharmacology: Promises and pitfalls Ageing Res Rev. 2016;31:9-35. doi: 10.1016/j.arr.2016.08.004.
3. World Report on Ageing and Health. Geneva: WHO. 2015.
4. Longo VD, Antebi A, Bartke A, et al. Interventions to Slow Aging in Humans: Are We Ready? Aging Cell. 2015; 14: 497-510.
5. Kennedy BK, Pennypack JK. Aging interventions get human. Oncotarget. 2015; 69:590-1. doi: 10.18632/oncotarget.3173.
6. Kennedy BK, Partridge L. 2nd interventions in aging conference. Aging (Albany NY). 201; 9: 1090-5.
7. Nadon NL, Strong R, Miller RA, Harrison DE. NIA Interventions Testing Program: Investigating Putative Aging Intervention Agents in a Genetically Heterogeneous Mouse Model. EBioMedicine. 2016; doi: 10.1016/j.ebiom.2016.11.038.
8. Anisimov VN, Popovich IG, Zabezhinski MA. Methods of testing pharmacological drugs effects on aging and life-span in mice. Methods in Molecular Biology 2013; 1048:145-160.
9. Anisimov VN, Zabezhinski MA, Popovich IG, et al. Rodent models for the preclinical evaluation of drugs suitable for pharmacological intervention in aging. Expert Opinion Drug Discovery. 2012; 7:85-95.
10. Anisimov V.N. Premature ageing prevention: Limitations and perspectives of pharmacological interventions. Current Drugs Targets, 2006;7(11):1485-1503.
11. Spindler SR. Review of the literature and suggestions for the design of rodent survival studies for the identification of compounds that increase health and life span. Age (Dordr). 2012; 34: 111-20. DOI: 10.1007/s11357-011-9224-6
12. Anisimov VN, Ukraintseva SV, Yashin AI. Cancer in rodents: Does it tell us about cancer in humans? Nature Rev. Cancer. 2005; 5 (10): 807-819.
13. Anisimov VN. Life span extension and cancer risk: myths and reality. Exp.Gerontol.2001; 26 (7):1101-1137.
14. Anisimov VN, Sidorenko AV. It is necessary to establish an International Agency for Research on Aging. Aging (Albany NY) 2018; 10: 863-867; doi: 10.18632/aging.101451.1.
15. Anisimov VN. Metfomin for cancer and aging prevention: is it a time to make the long story short? Oncotarget, 2015;6:39398-407.
16. Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM, Vinogradova IA. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim. Biophys. Acta. 2006; 1757: 573-589.
17. Neff F, Flores-Dominguez D, Ryan DP et al. Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest. 2013; 123: 3272-91.
18. Montesano R, Bartsch H, Vainio H, et al. IARC Sci Publ No 83. Lyon: IARC, 1986.
19. Aliper A, Belikov AV, Garazha A et al. In search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics of young healthy state. Aging (Albany NY). 2016;8: 2127-52.
Downloads
Published
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
